Sionna Therapeutics (SION) Q1 2026 earnings summary

Executive summary

• Focused on developing novel therapies for cystic fibrosis by stabilizing the CFTR protein's NBD1 domain and advancing complementary modulator candidates, including SION-719 and SION-451.

• Completed enrollment in a Phase 2a trial for SION-719 as an add-on to standard of care and initiated a Phase 1 dual combination trial for SION-451; topline data expected summer 2026.

• Encore data from previous studies to be presented at the 49th European Cystic Fibrosis Conference in June 2026.

• No product revenue generated to date; operations funded by equity offerings and an initial public offering.

Financial highlights

• Net loss of $26.8 million for Q1 2026, compared to $16.5 million for Q1 2025.

• Operating expenses rose to $29.6 million from $19.7 million year-over-year, driven by increased R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $289.9 million as of March 31, 2026.

• No revenue recognized; interest income was $2.8 million, down from $3.0 million year-over-year.

• Weighted-average shares outstanding increased to 44.9 million from 26.6 million year-over-year.

Outlook and guidance

• Existing cash and investments expected to fund operations into 2028, but substantial additional capital will be needed for future development and commercialization.

• Topline data from ongoing Phase 2a and Phase 1 trials anticipated in summer 2026.